NanoTYPE HLA-11 Plus

About Omixon

Omixon is a specialized diagnostics company focused on transitioning the HLA typing community from traditional methods to high-resolution Next-Generation Sequencing. Its core offerings are integrated NGS assay kits and proprietary analysis software designed for clinical histocompatibility labs, enabling more accurate matching for transplant patients. The company has achieved significant global adoption, with over 50 labs using its products in clinical routine. In 2024, Omixon was acquired by Werfen, a global in-vitro diagnostics company, integrating it into a larger commercial and regulatory framework.

Therapeutic Areas